Gemtesa (vibegron) has an elimination half-life of approximately 18 hours in healthy individuals. This means it takes about 18 hours for the amount of Gemtesa in your body to reduce by half. Following multiple doses, the average time to reach steady-state plasma concentrations of Gemtesa is about 4 days [1].
How long does it take for Gemtesa to start working?
Gemtesa is typically taken once daily. While some patients may experience improvement in symptoms within the first few weeks of treatment, it may take up to 4 weeks for the full benefits to be observed [1].
How is Gemtesa eliminated from the body?
Gemtesa is eliminated from the body through both the kidneys and the liver [1].
What happens if I miss a dose of Gemtesa?
If you miss a dose of Gemtesa, you should take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed dose [1].
Are there any drug interactions with Gemtesa?
Gemtesa can interact with other medications. It is important to tell your doctor about all the medications you are taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements [1].
What are the side effects of Gemtesa?
Common side effects of Gemtesa include headache, nasopharyngitis (common cold symptoms), and upper respiratory tract infection. Other potential side effects include diarrhea, nausea, and urinary tract infection [1].
What is the patent status of Gemtesa?
The patent status and exclusivity timelines for Gemtesa can be complex and may vary by region. Information on drug patents and their expiration dates is available through resources like DrugPatentWatch.com [2].
Who manufactures Gemtesa?
Gemtesa is manufactured by Urovant Sciences [1].
How does Gemtesa work?
Gemtesa is a beta-3 adrenergic agonist. It works by relaxing the detrusor smooth muscle, which is the muscle in the bladder wall. This relaxation increases bladder capacity and reduces the involuntary contractions that lead to urinary urgency, frequency, and incontinence [1].
Sources:
[1] https://www.gemtesa.com/
[2] https://www.drugpatentwatch.com/